EN DE
STOCK COMPARISON

Al Mohafaza Company for Educati vs Fredun Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Al Mohafaza Company for Educati (9598) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Al Mohafaza Company for Educati trades at SAR 25.80 versus a fair value of SAR 9.50 (-63%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).
Al Mohafaza Company for Educati
9598.SR · SAR · Industrials
-63%
upside to fair value
overvalued
PriceSAR 25.80
Fair ValueSAR 9.50
Quality32/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+77%
upside to fair value
undervalued
Price₹1,218
Fair Value₹2,155
Quality33/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Al Mohafaza Company for EducatiFredun Pharmaceuticals
Valuation
42.3×P/E (TTM)42.2×
1.95×P/S (TTM)2.23×
0.49×P/B5.03×
6.4×EV/EBITDA15.5×
1.9%Dividend yield0.0%
SAR 0.50Dividend per share₹0.70
Profitability
18%Net margin5%
23%Operating margin12%
4%Return on equity16%
2%Return on assets9%
Growth
4%Revenue growth (YoY)27%
11.2%Avg. growth/yr (3Y)32.2%
Avg. growth/yr (5Y)36.9%
Balance & size
Debt / equity0.20×
$55MMarket cap$149M
expensiveGrowth qualityexpensive

Al Mohafaza Company for Educati leads: 6 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Al Mohafaza Company for Educatiof which business quality 37 · market factors 57 Fredun Pharmaceuticalsof which business quality 35 · market factors 44
ProfitabilityMargins and returns on capital today
36
48
Quality GrowthAre margins and returns improving?
12
73
CashflowEarnings quality: real cash, not paper profit
35
5
Fin. StrengthBalance sheet, leverage, solvency risk
87
57
InvestmentDisciplined investing over empire-building
11
16
Low VolatilityCalm price path (market factor)
75
43
MomentumPrice trend over the last 3–12 months (market factor)
46
39
52W MomentumDistance to the 52-week high (market factor)
58
54
Net IssuanceBuybacks instead of dilution
9
7

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Al Mohafaza Company for Educati

Earnings-BasedSAR 6.92
Dividend DiscountSAR 4.37
MultiplesSAR 10.80
Asset-BasedSAR 9.37
Economic ProfitSAR 7.18
Growth EarningsSAR 11.72

14 of 14 models see the stock below the current price.

Fredun Pharmaceuticals

Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535

5 of 14 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Al Mohafaza Company for Educati
Bear SAR 7.58Fair Value SAR 9.50Bull SAR 11.91
SAR 25.80 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,509Fair Value ₹2,155Bull ₹2,802
₹1,218 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Al Mohafaza Company for Educati · Industrials

Quality score32 · bottom 25%
Fair value upside-63% · bottom 25%

Fredun Pharmaceuticals · Healthcare

Quality score33 · bottom 25%
Fair value upside+77% · Top 25%

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Al Mohafaza Company for Educati trades at SAR 25.80 versus a fair value of SAR 9.50 (-63%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).

Fredun Pharmaceuticals has the higher quality score (33/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.